Table 1.

Characteristics of case-control studies on ALDH2 polymorphisms and AD and PD risk.

References	Country	Control design	Genotype method	Case	Control	Genotype distribution						P for HWE	MAF	NOS evaluation	Disease type
						Case			Control
Rs671						GG	GA	AA	GG	GA	AA
Kamino et al. (15)	Japan	HB	PCR-RFLP	447	447	232	183	32	280	138	29	0.04	0.22	7	AD
Kim et al. (23)	Korea	PB	PCR-RFLP	80	610	60a	20b		435a	175b		NA	NA	7	AD
Wang et al. (24)	China	HB	PCR-RFLP	188	223	54	92	42	124	84	15	0.88	0.26	7	AD
Zhou et al., (25)	China	HB	PCR-RFLP	106	100	65	32	9	54	38	8	0.72	0.27	7	AD
Komatsu et al. (26)	Japan	PB	TaqMan	158	130	81	62	15	67	54	9	0.67	0.28	8	AD
Ma et al., (29)	China	HB	PCR-RFLP	115	236	72	30	13	177	52	7	0.20	0.14	7	AD
Zhang et al. (27)	China	HB	PCR-RFLP	584	582	321	236	27	339	208	35	0.68	0.24	9	PD
Zhao et al. (28)	China	HB	PCR-RFLP	115	214	71	32	12	157	52	5	0.78	0.14	7	PD
Rs4767944						CC	CT	TT	CC	CT	TT
Zhang et al. (27)	China	HB	PCR-RFLP	584	582	92	316	176	62	301	219	0.01	0.63	8	PD
Madadi et al. (30)	Iran	HB	PCR-RFLP	490	490	339	143	9	344	133	13	0.97	0.16	8	PD
Rs441						TT	TC	CC	TT	TC	TT
Zhang et al. (27)	China	HB	PCR-RFLP	584	582	281	278	25	293	256	33	0.02	0.28	8	PD

HWE in control.

NA, Not available.

^aData of the GG genotype;

^bData of the GA/AA genotypes.

HB, Hospital or healthy based; PB, Population based.

AD, Alzheimer's disease; PD, Parkinson's disease.